Phase II Study of S-1, a Novel Oral Derivative of 5-Fluorouracil, in Advanced Gastric Cancer

Publisher： Karger

E-ISSN： 1423-0232|58|3|191-197

ISSN： 0030-2414

Source： Oncology, Vol.58, Iss.3, 2000-04, pp. : 191-197

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

An Early Phase II Study of Oral S-1, a Newly Developed 5-Fluorouracil Derivative for Advanced and Recurrent Gastrointestinal Cancers

By  

Oncology, Vol. 57, Iss. 3, 1999-10 ,pp. : 202-210

Karger

Access to resources Recommend Favorite

Prevention of Peritoneal Metastasis of Human Gastric Cancer Cells in Nude Mice by S-1, a Novel Oral Derivative of 5-Fluorouracil

By  

Oncology, Vol. 64, Iss. 2, 2003-02 ,pp. : 176-182

Karger

Access to resources Recommend Favorite

Phase II Study of Bolus 5-Fluorouracil and Leucovorin Combined with Weekly Paclitaxel as First-Line Therapy for Advanced Gastric Cancer

By  

Oncology, Vol. 81, Iss. 5-6, 2011-11 ,pp. : 291-297

Karger

Access to resources Recommend Favorite

A Phase II Study of Infusional 5-Fluorouracil and Low-Dose Leucovorin with Docetaxel for Advanced Gastric Cancer

By  

Oncology, Vol. 70, Iss. 1, 2006-03 ,pp. : 63-70

Karger

Access to resources Recommend Favorite

High-Dose 5-Fluorouracil / Folinic Acid in Combination with Three-Weekly Mitomycin C in the Treatment of Advanced Gastric Cancer. A Phase II Study

By  

Oncology Research and Treatment, Vol. 25, Iss. 3, 2002-07 ,pp. : 255-260

Karger

Access to resources Recommend Favorite